MRManuela Cândido Amaral dos Reis

Manuela Cândido Amaral dos Reis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Manuela Cândido Amaral dos Reis has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Beyond the Adolescent Window: HPV Vaccination in Adult Women

    by Isadora Rodrigues Almeida, Marcela Fermoselle de Vita Silva, Thamy Cristina Campos, Talita Almeida Durães, Luana dos Santos Ribeiro, Manuela Cândido Amaral dos Reis, Gustavo Yano Callado, Antonio Braga, Edward Araujo Júnior, Gloria Calagna

    Human papillomavirus (HPV) vaccination has traditionally targeted girls and adolescents before sexual debut, when its preventive potential is greatest. However, many women reach adulthood unvaccinated or incompletely vaccinated, a gap widened by the COVID-19 pandemic. This narrative review summarizes the current evidence on HPV vaccination in adult women and its implications for gynecological practice. Sexual debut, previous infection, or a positive HPV test does not preclude benefit, because few women have been exposed to all vaccine types; nevertheless, the vaccine is prophylactic and does not treat established infection or lesions. In women aged 27 to 45 years, trials show favorable immunogenicity, efficacy, and safety, and vaccination is recommended through shared clinical decision-making that considers prior exposure and the risk of new exposures. Evidence above 45 years of age remains scarce. After excisional treatment of cervical intraepithelial neoplasia grade 2 or worse, meta-analyses predominantly based on observational studies suggest lower recurrence rates following adjuvant vaccination, although this benefit has not been consistently confirmed by randomized controlled trials. We also discuss additional vaccination with the nonavalent vaccine after bivalent or quadrivalent series, single-dose schedules, people living with HIV, and cervical screening in vaccinated women, in whom HPV-based testing maintains better performance than cytology. Missed opportunities remain common, and the absence of a recommendation from a health care professional is among the main reasons adults remain unvaccinated. Reviewing vaccination history at every gynecological visit, combined with individualized counseling, may help close the gap between vaccinated young cohorts and unvaccinated adult women and support cervical cancer elimination goals.

  • Open Access

    Maternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation

    by Isadora Rodrigues Almeida, Marcela Fermoselle de Vita Silva, Taline de Brito Cavalcante, Giovanna Alves de Britto, Manuela Cândido Amaral dos Reis, Luis Fernando Lima Bueno, Luana dos Santos Ribeiro, Gustavo Yano Callado, Susana Cristina Aidé Viviani Fialho, Antonio Braga, et al.

    Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young infants and accounts for substantial morbidity, hospitalization, and mortality worldwide, with the highest burden concentrated in the first months of life, when immunological and anatomical immaturity favors severe disease. Maternal vaccination has emerged as a strategy to bridge this window of vulnerability through the transplacental transfer of neutralizing antibodies. This integrative review synthesizes scientific articles published between 2022 and 2026, including systematic reviews, meta-analyses, narrative reviews, and position statements from national and international scientific societies, addressing the epidemiology, clinical manifestations, diagnosis, mechanism of action, efficacy, safety, and public health impact of maternal RSV immunization. The bivalent prefusion F protein vaccine (RSVpreF; Abrysvo®), administered as a single intramuscular dose between 32 and 36 weeks of gestation, induces maternal IgG that is transferred to the fetus and confers passive protection during the first six months of life. In the phase 3 MATISSE trial, vaccination demonstrated 81.8% efficacy against severe RSV lower respiratory tract infection within 90 days of birth and 69.4% within 180 days, alongside reductions in hospitalization. The safety profile was favorable, with predominantly mild and transient adverse events; a numerical imbalance in preterm birth remains under surveillance and underlies the precautionary gestational window. Maternal vaccination and long-acting monoclonal antibodies (nirsevimab) are best regarded as complementary rather than competing strategies. Current evidence supports maternal immunization as one of the most effective measures to reduce the burden of RSV disease in early infancy.